Breaking News, Collaborations & Alliances

Theramex, Enzene Biosciences Partner on Arthritis Treatment

Will develop and commercialize Tocilizumab, a biosimilar for the treatment of rheumatoid arthritis.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Theramex, a global specialty pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences to develop, register and commercialize a biosimilar drug of Roche’s reference medicine RoActemra (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialized from 2026 in Europe, the UK, Switzerland, and Australia.   Theramex’s Tocilizumab product will be available i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters